Galecto Inc (GLTO): Total Asset Value of Company

Graphic logo of Galecto Corp (GLTO)

The development of anti-fibrosis agents relies on complex international transportation of biosamples under strict temperature regimes. Galecto, Inc. (GLTO) is currently fighting for its reputation following test failures, striving to validate the value of its assets. This chart of current share prices on GURU.Markets reflects total assets at 17.05. Unique patents and stringent FDA oversight create a high barrier to entry, limiting the emergence of new players.

Galecto, Inc. (GLTO) Company Total Assets: for the period 07/04/2022 - 03/10/2026

Comprehensive metric breakdowns and analytics for Galecto Corp (GLTO)

- price and consensus price forecast:
Market Price galecto.com|GLTO - Price Target Chart
- market capitalization data:
Market Valuation Galecto Corporation|GLTO - Enterprise Value
- book capitalization data:
Accounting Value of a Share Galecto|GLTO - Book Capitalization|Market Capitalization to Book Value Ratio galecto.com|GLTO - Aggregate Company Assets
- debt and liquidity data:
All Debt to Shareholders' Equity Ratio Galecto, Inc.|GLTO - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Galecto Corporation|GLTO - Company Aggregate Debts|Debts to Book Capitalization Galecto Corporation
Fundamental valuation:GLTO, galecto.com
Finished products of Galecto, Inc.

This indicator reflects the total resource volume of Galecto, Inc. (GLTO), reverse-calculated via return on assets (ROA), allowing investors to assess capital efficiency and the impact of leverage on the balance sheet. By analyzing the company's total assets, one can trace the financial foundation for Galecto, Inc. (GLTO) to expand into oncology and fibrosis therapy segments through the development of its galectin inhibitor pipeline.

Competitors of Galecto, Inc. (GLTO)

ASND (ascendispharma.com) - Company Assets|Aggregate Company Assets Madrigal Pharmaceuticals, Inc. MDGL|Total Asset Value of Company Corcept Therapeutics Inc.|Rhythm Pharmaceuticals Inc (RYTM) - Company Total Assets|Aggregate Asset Value Akero Corp (AKRO)|Company Total Assets MTSR (Metsera Inc)|moonlaketx.com - Company Total Assets|Aggregate Company Assets Crinetics (CRNX)|NAMS: Aggregate Asset Value|SLNO (Soleno) - Aggregate Company Assets|Amicus Corp (FOLD) - Cumulative Company Assets|ETNB (89bio, Inc.) - Company Total Assets|Company Total Assets agios.com (AGIO)|Structure Therapeutics Inc. (GPCR) - Cumulative Company Assets|Aggregate Asset Value MDXG (MiMedx Group Inc)|Rezolute Corp - Aggregate Company Assets|Cumulative Company Assets Lexicon Corp LXRX|MBX (MBX Biosciences Inc) - Company Total Assets|altimmune.com (ALT) - Company Assets|AARD - Cumulative Company Assets|Sagimet Biosciences, Inc. (SGMT) - Aggregate Business Assets|BIOA (BioAge Labs Inc.) - Company Total Assets|Company Total Assets Biomea Fusion Corp|Company Total Assets Quince Therapeutics (QNCX)|Aggregate Company Assets GUTS (fractyl.com)|VTVT: Aggregate Company Assets|Agape ATP Corp - Company Assets|PLUR - Aggregate Company Assets|SYBX - Aggregate Company Assets|Lipocine Inc. - Company Total Assets|MTNB (Matinas BioPharma Holdings) - Company Total Asset Base|SPRB: Aggregate Company Assets|Company Total Asset Base CTCX|Aggregate Company Assets LUMO (Lumos Pharma Corp)|Cumulative Company Assets Organovo Corp (ONVO)|RDUS (Radius Recycling, Inc.) - Company Total Assets